Cumulus cloud

SFLMaven Corp. Announces the Appointment of Chad MacKay as Chairman and CEO and Announces New Business Plan

Retrieved on: 
Tuesday, November 15, 2022
Cumulus cloud, OTC Markets Group, Organization, Loyal Company of Virginia, University, Chase N Dough, RAD, Security (finance), Lithium, Acquisition, Keeper, Risk management

Mr. MacKay is the cofounder and managing partner of Loyal Companies, a private equity firm focusing on mergers and acquisitions.

Key Points: 
  • Mr. MacKay is the cofounder and managing partner of Loyal Companies, a private equity firm focusing on mergers and acquisitions.
  • Mr. MacKay has been active in philanthropy supporting children and families that have physical and/or mental challenges.
  • I am very excited to become a part of SFLMaven Corp as the Companys Chairman and CEO.
  • The Companys previous Chairman and CEO, Joseph Ladin, resigned as Chairman and CEO as part of these changes.

World-Class Forum for Life Science Innovation CNS Summit Taps Cumulus Neuroscience to Share New Data

Retrieved on: 
Thursday, November 10, 2022
Neuropsychiatry, Neurological disorder, Central Waqf Council, Medidata Solutions, Neurology, Science, Research, Health, Diagnosis, Dementia, Brain, HIV disease progression rates, LifeArc, Machine learning, Time, ML, Biomarker, Company, Clinical trial, Alzheimer's disease, Patient, Heart, Central nervous system, Industry, MD, CNS, Caregiver, Pharmaceutical industry, Medical imaging, Cumulus cloud

"At the heart of scientific innovation is collaboration and knowledge sharing," said Dr. Bhatti. "The CNS Summit gathers the life sciences community united around a shared goal -- to accelerate innovation and improve patient experience and outcomes. We are honored to not only attend alongside and learn from these leaders but to present our own vital research and discuss the future of research, diagnosis and treatment for neuropsychological conditions."

Key Points: 
  • "At the heart of scientific innovation is collaboration and knowledge sharing," said Dr. Bhatti.
  • "The CNS Summit gathers the life sciences community united around a shared goal -- to accelerate innovation and improve patient experience and outcomes.
  • The CNS Summit takes place from November 17-20 in Boca Raton, Florida, and brings together leading pharma and biotech executives dedicated to innovating care in the life sciences.
  • Cumulus Neuroscience is a leader in advancing clinical trial data, creating tools for its partners to harness data, and transforming and accelerating diagnosis and care for patients with central nervous system disorders.

Introducing Cumulus 2023, An Ecosystem Event Focused on the Future of Food

Retrieved on: 
Wednesday, September 21, 2022
FarmWise, Lettuce, Center, Adam, Learning, Connectivism, Industry, Resort hotel, Technology, Boston Consulting Group, L.E.K. Consulting, Leadership, Ecosystem, Monarch, Food, Avi, Education, Agriculture, Financial services, Cumulus cloud

NEW YORK, Sept. 21, 2022 /PRNewswire-PRWeb/ -- Connectiv, a highly-successful events incubator, announces the launch of Cumulus, a three-day event (April 17-19, 2023) that will gather the entire ecosystem of innovators, investors and industry leaders that are changing the future of food. Focused on technology trends from seed or cell downstream to restaurant or retail, Cumulus will offer three days of learning, collaboration, and world-class networking opportunities at The Venetian Resort Hotel in Las Vegas.

Key Points: 
  • Food ingredients, food production, food delivery, even food sales are in the midst of massive change and innovation, and there's no place in the world that isn't touched by the transformation.
  • And, Cumulus will be the place that gathers the smartest minds from across the industry and the globe.
  • "Cumulus exists to catalyze the global food industry by bringing together a never-before assembled group and helping them meet each other."
  • "This is a unique opportunity to forge cross-sector conversation and collaboration across previously siloed parts of the food ecosystem."

Cumulus Neuroscience Appoints Digital Health and Pharmaceutical Executive Aman Bhatti, MD as Chief Executive Officer

Retrieved on: 
Wednesday, September 21, 2022
Alivecor, Health care, Central nervous system, Central Waqf Council, Face, GSK, Industry, Patient, Physician, Technology, NIHR, Drug development, Dementia, Sleep, Reckitt, Disease, Time, Company, DDF, Neurological disorder, Doctor of Philosophy, Science, LifeArc, Nicorette, MD, J&J, Health, Language, Thought, CEO, Biopharma LLC, Novartis, HIV disease progression rates, ML, Neurodegeneration, Machine learning, Brain, Psychiatry, Biomarker, Cros, Solution, Diagnosis, Caregiver, CNS, EEG, Pfizer, Pharmaceutical industry, Medical imaging, Takeda, Neurology, Cumulus cloud, Sanofi, Neuropsychiatry, Alzheimer's disease

BELFAST, Northern Ireland, and BRIDGEWATER, N.J., Sept. 21, 2022 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; the Company), a global digital health company developing multi-domain digital biomarkers for the brain, today appointed Aman Bhatti, MD, as Chief Executive Officer (CEO). Dr. Bhatti, a noted digital health executive with experience launching and scaling world-renowned consumer healthcare brands, joins Cumulus as the Company shifts toward healthcare and expands biopharma partnerships in its next growth phase. Dr. Bhatti's appointment follows the recent award of a £1.5M UK National Institute for Health and Care Research (NIHR) grant to Cumulus and its academic research partners, using the Cumulus platform to improve early dementia diagnosis. 

Key Points: 
  • Tapping AliveCor Senior Executive, Cumulus Signals Progression To A Global Healthcare Company; Dr. Bhatti To Lead Expansion of AI-Based Digital Biomarker Platform To Accelerate Patient Care and Drug Development in Neurology and Neuropsychiatry
    BELFAST, Northern Ireland, and BRIDGEWATER, N.J., Sept. 21, 2022 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; the Company), a global digital health company developing multi-domain digital biomarkers for the brain, today appointed Aman Bhatti, MD, as Chief Executive Officer (CEO).
  • Dr. Bhatti, a noted digital health executive with experience launching and scaling world-renowned consumer healthcare brands, joins Cumulus as the Company shifts toward healthcare and expands biopharma partnerships in its next growth phase.
  • "Neurological disorders are a global health issue, and digital biomarkers which require integrated, multi-domain assessment technologies are key to supporting faster drug development, disease diagnosis, and therapeutic solutions," said Ruth McKernan, PhD, co-founder & executive chair, Cumulus.
  • The Company is supported by highly experienced specialized investors, DDF/SV Health Investors, LifeArc and Future Fund, and a world-class Scientific and Technical Advisory Board.

Cumulus Neuroscience Appoints Digital Health and Pharmaceutical Executive Aman Bhatti, MD as Chief Executive Officer

Retrieved on: 
Wednesday, September 21, 2022
Alivecor, Health care, Central nervous system, Central Waqf Council, Face, GSK, Industry, Patient, Physician, Technology, NIHR, Drug development, Dementia, Sleep, Reckitt, Disease, Time, Company, DDF, Neurological disorder, Doctor of Philosophy, Science, LifeArc, Nicorette, MD, J&J, Health, Language, Thought, CEO, Biopharma LLC, Novartis, HIV disease progression rates, ML, Neurodegeneration, Machine learning, Brain, Psychiatry, Biomarker, Cros, Solution, Diagnosis, Caregiver, CNS, EEG, Pfizer, Pharmaceutical industry, Medical imaging, Takeda, Neurology, Cumulus cloud, Sanofi, Neuropsychiatry, Alzheimer's disease

BELFAST, Northern Ireland, and BRIDGEWATER, N.J., Sept. 21, 2022 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; the Company), a global digital health company developing multi-domain digital biomarkers for the brain, today appointed Aman Bhatti, MD, as Chief Executive Officer (CEO). Dr. Bhatti, a noted digital health executive with experience launching and scaling world-renowned consumer healthcare brands, joins Cumulus as the Company shifts toward healthcare and expands biopharma partnerships in its next growth phase. Dr. Bhatti's appointment follows the recent award of a £1.5M UK National Institute for Health and Care Research (NIHR) grant to Cumulus and its academic research partners, using the Cumulus platform to improve early dementia diagnosis.   

Key Points: 
  • Tapping AliveCor Senior Executive, Cumulus Signals Progression To A Global Healthcare Company; Dr. Bhatti To Lead Expansion of AI-Based Digital Biomarker Platform To Accelerate Patient Care and Drug Development in Neurology and Neuropsychiatry
    BELFAST, Northern Ireland, and BRIDGEWATER, N.J., Sept. 21, 2022 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; the Company), a global digital health company developing multi-domain digital biomarkers for the brain, today appointed Aman Bhatti, MD, as Chief Executive Officer (CEO).
  • Dr. Bhatti, a noted digital health executive with experience launching and scaling world-renowned consumer healthcare brands, joins Cumulus as the Company shifts toward healthcare and expands biopharma partnerships in its next growth phase.
  • "Neurological disorders are a global health issue, and digital biomarkers which require integrated, multi-domain assessment technologies are key to supporting faster drug development, disease diagnosis, and therapeutic solutions," said Ruth McKernan, PhD, co-founder & executive chair, Cumulus.
  • The Company is supported by highly experienced specialized investors, DDF/SV Health Investors, LifeArc and Future Fund, and a world-class Scientific and Technical Advisory Board.

Bechtel and Cumulus: Increasing Productivity Through Digital Solutions

Retrieved on: 
Tuesday, September 6, 2022
Software, Partnership, CEO, Technology, Safety, Government, Engineering, Carbon, STS, Anchorage Air Route Traffic Control Center, Bechtel, Workflow, Digital Systems, Conference, Control center, Mobile app, Industry, Renewable energy, Satellite navigation device, Cumulus cloud

BOSTON, Sept. 6, 2022 /PRNewswire/ -- Cumulus Digital Systems, a global technology platform enabling connected work, today announced a successful partnership with Bechtel to deploy a bolted joint management system at scale. In addition to enforcing engineering controls and improving productivity, the deployment also successfully reduced the bolted connection leak rate to 0.1 percent, a 100 times reduction compared to the industry average of 10 percent.

Key Points: 
  • "The strong results from our partnership with Bechtel demonstrate the value that digitalization brings to construction," said Matthew Kleiman, CEO of Cumulus.
  • "We are excited to take this partnership even further and continue to use technology to eliminate rework and enable greater work transparency."
  • Furthering their commitment to reduce emissions and improve safety, Bechtel elected to implement Cumulus Smart Torque System (STS) during the construction of the Pennsylvania Chemicals project.
  • Bechtel has spent more than a century helping customers navigate shifts in energy consumption, technological change, financing challenges, and a sharpening focus on sustainable alternatives.

Nodus Oncology launches, founded by Cumulus Oncology and in partnership with the Lead Discovery Center, to focus on developing first and best-in-class molecules inhibiting novel DNA damage response targets

Retrieved on: 
Tuesday, September 6, 2022
AstraZeneca, Partnership, D, NewCo, CEO, Cancer, Research, Oncology, Max Planck Society, Doctor of Philosophy, VC, DDR, DNA, Daiichi Sankyo, MBA, Antibody, LDC, DNA repair, Merck Group, Boehringer Ingelheim, Drug discovery, Industry, McAuliffe-Shepard Discovery Center, Apeiron, Management, Pharmaceutical industry, Medical imaging, Bayer, Cumulus cloud, Glossary of entomology terms

Nodus is led by Chief Executive Officer Dr Ian Waddell PhD, Chief Scientific Officer of Cumulus Oncology.

Key Points: 
  • Nodus is led by Chief Executive Officer Dr Ian Waddell PhD, Chief Scientific Officer of Cumulus Oncology.
  • LDC will act as the drug discovery arm of Nodus and participate in the development of all assets in Nodus pipeline.
  • Nodus Oncologys pipeline is focused on a number of novel small molecules targeting specific vulnerabilities in the DNA damage response.
  • Founded by Cumulus Oncology, which contributes capital and oncology discovery and development expertise to the creation of new biotech companies, Nodus has received seed investment from both Cumulus Oncology and additional investors.

Cumulus Media Creates Music Partnerships Division

Retrieved on: 
Monday, August 29, 2022
CMLS, VP, Master, Academy of Country Music Awards, AP, Radio, Philips, NASDAQ, Music, Academy, Westwood One, NCAA, Cumulus Media, CNN, GLOBE, Leadership, News, NFL, Industry, VPS, Country music awards, Marketing, Cumulus cloud

ATLANTA, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Cumulus Media (NASDAQ: CMLS) today announced VP of Programming Operations Greg Frey has been tapped to lead Music Partnerships, a new division within Cumulus, as VP, Music Partnerships.

Key Points: 
  • ATLANTA, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Cumulus Media (NASDAQ: CMLS) today announced VP of Programming Operations Greg Frey has been tapped to lead Music Partnerships, a new division within Cumulus, as VP, Music Partnerships.
  • Frey will front the team which will develop music marketing partnerships for Cumuluss 300+ music stations, Westwood One network franchises, and related social/digital platforms.
  • The teams focus will be on enhancing partnerships, creating value for the music industry as well as new content and revenue opportunities for Cumulus.
  • Cumulus Media is the only audio media company to provide marketers with local and national advertising performance guarantees.

Cumulus Media Appoints Deborah Farrington to Board of Directors

Retrieved on: 
Monday, August 22, 2022
CMLS, Master, CEO, Prison, Fortune 500, Merrill (company), AP, NYSE, Academy of Country Music Awards, Public sector banks in India, LP, Radio, Achievement, NASDAQ, HCM, Triple accreditation, Entrepreneurship, Trustee, Financial services, Academy, Oracle, Board, NCAA, NetSuite, Westwood One, RBAC, Director, Cumulus Media, Capital, CNN, Chase Bank, MBA, Smith College, GLOBE, Company, Cumulus cloud, News, NCR, Harvard Business School, Country music awards, NFL, Woman, Growth, Acquisition, Holding company, Management

ATLANTA, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Cumulus Media Inc. (NASDAQ: CMLS) today announced that Deborah Farrington, Co-Founder and Managing Partner of StarVest Partners, LP, has been appointed to the Cumulus Media Board of Directors.

Key Points: 
  • ATLANTA, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Cumulus Media Inc. (NASDAQ: CMLS) today announced that Deborah Farrington, Co-Founder and Managing Partner of StarVest Partners, LP, has been appointed to the Cumulus Media Board of Directors.
  • Deborah is a highly respected and accomplished venture capital pioneer and experienced board member of Fortune 500 and leading public technology companies, said Mary G. Berner, President and Chief Executive Officer of Cumulus Media.
  • I am honored to join the Cumulus Media Board at such an exciting time for the Company, said Farrington.
  • Cumulus Media is the only audio media company to provide marketers with local and national advertising performance guarantees.

New study highlights superior efficacy of at-home dry EEG assessment compared to lab-based monitoring

Retrieved on: 
Wednesday, August 10, 2022
Paper, Dementia, System, HIV disease progression rates, EEG, School of Psychology, Bangor University, CNS, Clinical trial, Cognition, School, LifeArc, Research, Method, Institute, Patient, Science, Frontiers, Company, Trinity College Dublin, Lists of diseases, Central nervous system, Trinity College, Netherlands Institute for Neuroscience, Central Waqf Council, Collection, Time, Digital health, University, Medical imaging, Medical device, Psychology, Cumulus cloud, Psychiatry, Neuroscience

Cumulus' integrated digital and physiological biomarker platform provides wireless "dry" EEG recording systems and easy-to-use engaging tasks that can be operated repeatedly by users at home.

Key Points: 
  • Cumulus' integrated digital and physiological biomarker platform provides wireless "dry" EEG recording systems and easy-to-use engaging tasks that can be operated repeatedly by users at home.
  • This provides a dramatically lower trial burden for patients and greater opportunity for the collection of real-world, longitudinal data compared to traditional lab-based, "wet" EEG.
  • Usability of the EEG system was evaluated via participant adherence and qualitative feedback using the System Usability Scale.
  • The study found that home-based gamified dry EEG in aggregate has superior precision to single in-lab based sessions, and that only 2 to 4 dry EEG sessions are required to match the quality of wet EEG recordings.